Hypnion Inc. is a wholly owned subsidiary of Eli Lilly and Company (www.lilly.com).  We are focused on the development of novel therapeutics for the treatment of central nervous system (CNS) disorders to serve the vastly underserved markets of sleep and wake-alertness disorders and circadian rhythm abnormalities.

Utilizing our proprietary drug discovery technology, SCORE-2004™, the world’s only predictive sleep-wake bioassay system, we are able to rapidly and accurately measure a drug’s impact on a wide spectrum of sleep and wake parameters, in a manner that is highly predictive of the human condition.

By accelerating the R&D process, from target validation and lead optimization, to successful clinical trial execution, SCORE-2004 provides a unique and compelling competitive advantage.